MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

the potential of their Flow Electroporation® technology and ExPERT™ platform in the field of gene-edited cell therapeutics. By allowing Vittoria to utilize their innovative technology, MaxCyte is enabling the development and production of cutting-edge gene-edited cell therapies for T-cell lymphoma. Vittoria's lead program, Viper 101, is a promising gene-edited cell therapy specifically designed ..